Search results for: Indication-Based Pricing
Filter search results
Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward
1 December 2018
…current approaches to MIP in Europe, the perceived challenges, and how they could be tackled in the future. Multi-indication pricing (MIP) is based on the idea of recognising the value…
Collaborating on Payment Models to Unlock the Potential of Multi-Indication Therapies.
22 June 2022, 2:00pm
Innovation in drug development is evolving at pace. Individual medicines are increasingly found to benefit patients in a range of indications within or across diseases, at different stages of disease,…
Delivering the Triple Win: A Value-Based Approach to Pricing
20 April 2023
…Extent value-based pricing to the indication level We also recommend that stakeholders maximise the benefits of value-based pricing, through complementary tools: Use outcomes-based managed entry agreements to manage residual uncertainty…
Recent Statistics on Orphan Approvals in Scotland and England
23 August 2011
…the 74 orphan indications approved by the European Medicines Agency (EMA) up to May 2011. The SMC has issued 55 decisions for the 74 orphan indications. Because of resubmissions and…
OHE at AES 2016: Early Access Schemes, Equity Adjusted QALYs, Multi-indication Pricing and Formulary Development
2 August 2016
…their activity. Multi-Indication Pricing: Pros, Cons and Applicability to the UK by Jorge Mestre-Ferrandiz Multi-indication pricing (MIP) involves setting a different price for each indication approved for a medicine. The…
A Framework for Value-aligned Pricing of Combination Therapies
25 June 2024
…accepted pricing models in Europe represents a barrier to their access. Drawing learnings from multi-indication pricing, we propose the adoption of strategies that support combination-based differential pricing (CBDP). We outline…
Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK
31 March 2015
…Institute for Health and Care Excellence (NICE). These activities are impeded if medicine use cannot be ascribed to indication. For example, multi-indication medicines were left out altogether from reports by…
Rare Disease Day 2024: Why Do We Care About Rare?
29 February 2024
…models for multi-indication medicines, Cole et al. highlighted how permitting price to vary by indication could incentivise R&D into the use of existing drugs for rare and untreated disorders which…
Is Rate Of Return Pricing A Useful Approach When Value-Based Pricing Is Not Appropriate?
22 March 2019
Value-based pricing (VBP) is an efficient method for pricing new drugs. Rate of return pricing could, however, be useful in two cases: treatments for ultra-rare diseases, and ‘cures’ for conditions…